Modulatory effects of bortezomib on host immune cell functions

Samuel Troy Pellom, Duafalia Fred Dudimah, Menaka Thounaojam, Thomas Joseph Sayers, Anil Shanker

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.

Original languageEnglish (US)
Pages (from-to)1011-1022
Number of pages12
JournalImmunotherapy
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Apoptosis
Proteasome Inhibitors
Proteasome Endopeptidase Complex
Ubiquitin
Chemokines
Neoplasms
Proteins
Lymphocytes
Cytokines
Ligands
Bortezomib
Growth
Therapeutics

Keywords

  • B cells
  • NK cells
  • T cells
  • bortezomib
  • chemokine
  • cytokine
  • dendritic cells
  • immunity
  • inflammation
  • ligands
  • lymphocyte receptors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Pellom, S. T., Dudimah, D. F., Thounaojam, M., Sayers, T. J., & Shanker, A. (2015). Modulatory effects of bortezomib on host immune cell functions. Immunotherapy, 7(9), 1011-1022. https://doi.org/10.2217/imt.15.66

Modulatory effects of bortezomib on host immune cell functions. / Pellom, Samuel Troy; Dudimah, Duafalia Fred; Thounaojam, Menaka; Sayers, Thomas Joseph; Shanker, Anil.

In: Immunotherapy, Vol. 7, No. 9, 01.09.2015, p. 1011-1022.

Research output: Contribution to journalReview article

Pellom, ST, Dudimah, DF, Thounaojam, M, Sayers, TJ & Shanker, A 2015, 'Modulatory effects of bortezomib on host immune cell functions', Immunotherapy, vol. 7, no. 9, pp. 1011-1022. https://doi.org/10.2217/imt.15.66
Pellom, Samuel Troy ; Dudimah, Duafalia Fred ; Thounaojam, Menaka ; Sayers, Thomas Joseph ; Shanker, Anil. / Modulatory effects of bortezomib on host immune cell functions. In: Immunotherapy. 2015 ; Vol. 7, No. 9. pp. 1011-1022.
@article{a30ecea84a414f17b60d3beb7e0b6f75,
title = "Modulatory effects of bortezomib on host immune cell functions",
abstract = "Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.",
keywords = "B cells, NK cells, T cells, bortezomib, chemokine, cytokine, dendritic cells, immunity, inflammation, ligands, lymphocyte receptors",
author = "Pellom, {Samuel Troy} and Dudimah, {Duafalia Fred} and Menaka Thounaojam and Sayers, {Thomas Joseph} and Anil Shanker",
year = "2015",
month = "9",
day = "1",
doi = "10.2217/imt.15.66",
language = "English (US)",
volume = "7",
pages = "1011--1022",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Modulatory effects of bortezomib on host immune cell functions

AU - Pellom, Samuel Troy

AU - Dudimah, Duafalia Fred

AU - Thounaojam, Menaka

AU - Sayers, Thomas Joseph

AU - Shanker, Anil

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.

AB - Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.

KW - B cells

KW - NK cells

KW - T cells

KW - bortezomib

KW - chemokine

KW - cytokine

KW - dendritic cells

KW - immunity

KW - inflammation

KW - ligands

KW - lymphocyte receptors

UR - http://www.scopus.com/inward/record.url?scp=84946758547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946758547&partnerID=8YFLogxK

U2 - 10.2217/imt.15.66

DO - 10.2217/imt.15.66

M3 - Review article

VL - 7

SP - 1011

EP - 1022

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 9

ER -